Immunovant, Inc. (IMVT) stock
IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
$33.21−0.07 (-0.21%)
Close on Nov 17, 2026Market cap $6.86BP/E –Yield –
Immunovant cash
Cash and short-term investments held at the end of each period.
Immunovant's cash was $797.80M at Jun 30, 2026. For fiscal 2026 it was $902.11M, up 26.4% from the year before. The highest annual figure on record is $902.11M in fiscal 2026.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $902.11M | +26.4% |
| FY2025 | Mar 31, 2025 | $713.97M | +12.4% |
| FY2024 | Mar 31, 2024 | $635.37M | +68.7% |
| FY2023 | Mar 31, 2023 | $376.53M | -23.8% |
| FY2022 | Mar 31, 2022 | $493.82M | +23.4% |
| FY2021 | Mar 31, 2021 | $400.15M | +297.9% |
| FY2020 | Mar 31, 2020 | $100.57M | +1339.8% |
| FY2019 | Mar 31, 2019 | $6.99M | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $797.80M | +33.2% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $902.11M | +26.4% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $994.53M | +165.4% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $521.87M | +10.3% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $598.91M | +6.9% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $713.97M | +12.4% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $374.69M | -45.8% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $472.94M | +75.2% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $560.01M | +69.7% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $635.37M | +68.7% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $690.94M | +59.7% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $269.93M | -33.5% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $329.96M | -22.8% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $376.53M | -23.8% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $432.61M | -17.9% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $405.77M | -27.4% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $427.21M | +12.7% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $493.82M | +23.4% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $527.00M | +24.9% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $558.95M | +25.8% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $379.01M | +35.2% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $400.15M | +297.9% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $421.97M | +2121.9% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $444.37M | +11132.9% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $280.28M | +3912.6% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $100.57M | +731.0% |
| Q3 FY2020CQ4 2018 | Sep 30, 2019 | $18.99M | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $3.96M | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $6.99M | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $12.10M | – |
See a number that looks wrong?